The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Robert S. Rosenson

Preventive Cardiology Center

Northwestern University Medical School

Chicago

IL 60611

USA

[email]@northwestern.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Preventive Cardiology Center, Northwestern University Medical School, Chicago, IL 60611, USA. 2001 - 2006
  • Preventive Cardiology Center, Division of Cardiology, Department of Medicine and Preventive Medicine, Northwestern University Medical School, USA. 2001 - 2005
  • The Feinberg School of Medicine, Division of Cardiology, Chicago, IL 60611, USA. 2005
  • Northwestern University Medical School, Preventive Cardiology Center, Division of Cardiology, Chicago, USA. 2001 - 2004
  • Department of Medicine and Preventive Medicine, Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, USA. 2002 - 2004
  • Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, USA. 2003
  • Department of Medicine and Pathology, Lipoprotein and Hemorheology Research Facility, Preventive Cardiology Center, Rush-Presbyterian-St. Luke's Medical Center, USA. 2001 - 2002

References

  1. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Rosenson, R.S. Am. Heart J. (2006) [Pubmed]
  2. Critical appraisal of revised cholesterol guidelines for the very high-risk patient. Rosenson, R., Lloyd-Jones, D. Expert. Rev. Cardiovasc. Ther (2005) [Pubmed]
  3. Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects. Rosenson, R.S., Tangney, C.C., Levine, D.M., Parker, T.S., Gordon, B.R. J. Lab. Clin. Med. (2005) [Pubmed]
  4. HDL-C and the diabetic patient: target for therapeutic intervention?. Rosenson, R.S. Diabetes Res. Clin. Pract. (2005) [Pubmed]
  5. Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. Rosenson, R.S. Curr. Opin. Cardiol. (2005) [Pubmed]
  6. Short-term reduction in bone markers with high-dose simvastatin. Rosenson, R.S., Tangney, C.C., Langman, C.B., Parker, T.S., Levine, D.M., Gordon, B.R. Osteoporos. Int (2005) [Pubmed]
  7. Assessing risk across the spectrum of patients with the metabolic syndrome. Rosenson, R.S. Am. J. Cardiol. (2005) [Pubmed]
  8. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia. Rosenson, R.S., Wolff, D., Tangney, C.C. Clin. Sci. (2004) [Pubmed]
  9. Current overview of statin-induced myopathy. Rosenson, R.S. Am. J. Med. (2004) [Pubmed]
  10. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Rosenson, R.S. Atherosclerosis (2004) [Pubmed]
  11. Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Rosenson, R.S., Reasner, C.A. Curr. Opin. Cardiol. (2004) [Pubmed]
  12. Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia. Rosenson, R.S., Tangney, C.C., Levine, D.M., Parker, T.S., Gordon, B.R. Atherosclerosis (2004) [Pubmed]
  13. Statins: can the new generation make an impression?. Rosenson, R.S. Expert. Opin. Emerg. Drugs (2004) [Pubmed]
  14. Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day. Rosenson, R.S., Bays, H.E. Am. J. Cardiol. (2003) [Pubmed]
  15. Modulating atherosclerosis through inhibition or blockade of angiotensin. Rosenson, R.S. Clin. Cardiol (2003) [Pubmed]
  16. Antiatherothrombotic effects of nicotinic acid. Rosenson, R.S. Atherosclerosis (2003) [Pubmed]
  17. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Rosenson, R.S. Expert. Rev. Cardiovasc. Ther (2003) [Pubmed]
  18. Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. Rosenson, R.S., Shott, S., Tangney, C.C. Atherosclerosis (2002) [Pubmed]
  19. High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. Rosenson, R.S., Koenig, W. Curr. Opin. Cardiol. (2002) [Pubmed]
  20. The rationale for combination therapy. Rosenson, R.S. Am. J. Cardiol. (2002) [Pubmed]
  21. Elevated blood viscosity in systemic lupus erythematosus. Rosenson, R.S., Shott, S., Katz, R. Semin. Arthritis Rheum. (2001) [Pubmed]
  22. Variability in fibrinogen measurements: an obstacle to cardiovascular risk stratification. Rosenson, R.S., Mosca, L., Staffileno, B.A., Tangney, C.C. Atherosclerosis (2001) [Pubmed]
  23. Lipid lowering therapy as an important adjunct to stroke prevention in coronary heart disease patients. Rosenson, R.S. Drugs. Today (2001) [Pubmed]
  24. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Rosenson, R.S. Am. J. Cardiovasc. Drugs (2001) [Pubmed]
 
WikiGenes - Universities